UACR

Everly Health and National Kidney Foundation Partnership Aims to Save Lives Through Early Detection of Chronic Kidney Disease

Retrieved on: 
Monday, February 5, 2024
Other Health, General Health, Philanthropy, Telemedicine, Virtual Medicine, Biometrics, Hospitals, Health Technology, Fitness & Nutrition, Foundation, Cardiology, Practice Management, Health, Diabetes, Glycated hemoglobin, Partnership, Kidney, National Kidney Foundation, Cholesterol, Knowledge, Prediabetes, National Committee, Quality assurance, Biomarker, UACR, Patient, NCQA, Diagnosis, Collection, Glomerular filtration rate, MBA, Kidney disease, MPH, Hypertension, Risk, CMS, Education, Heart, EGFR, Chronic kidney disease, Medicare, HEDIS, Pharmaceutical industry

“We are excited to partner with Everly Health to expand education on chronic kidney disease and two of its major risk factors, diabetes and hypertension,” said Joseph Vassalotti, MD, Chief Medical Officer at the National Kidney Foundation.

Key Points: 
  • “We are excited to partner with Everly Health to expand education on chronic kidney disease and two of its major risk factors, diabetes and hypertension,” said Joseph Vassalotti, MD, Chief Medical Officer at the National Kidney Foundation.
  • The new test suite includes Heart and Kidney Health Test, Diabetes Monitoring Test, Kidney Health Test, and Heart Health Test as part of preventive care screening.
  • Everly Health Solutions and a national health plan recently launched a kidney health pilot program to distribute Everly Health’s Kidney Health Tests to over 10,000 members.
  • For more information about the Everly Health Solutions diabetes monitoring and kidney health testing suite, visit https://www.everlyhealthsolutions.com/ .

New Interim, Real-World Data Provides Additional Insights on Hyperkalemia and Safety of Kerendia® (finerenone) for Patients with Chronic Kidney Disease Associated with Type 2 Diabetes

Retrieved on: 
Saturday, November 4, 2023
Biotechnology, Diabetes, Health, Pharmaceutical, Clinical Trials, Enzyme inhibitor, Incidence, Hyperkalemia, EGFR, Observational study, MD, Kidney disease, Type 2 diabetes, UACR, Society, Chronic kidney disease, Disease, ASN, Risk, T2D, See, CKD, Safety, Hospital, Patient, Heart failure, Insulin, Pharmaceutical industry, Bayer, Finerenone

Bayer today announced new interim, real-world data on Kerendia® (finerenone) that complement the hyperkalemia and safety data in its pivotal trials.

Key Points: 
  • Bayer today announced new interim, real-world data on Kerendia® (finerenone) that complement the hyperkalemia and safety data in its pivotal trials.
  • The data was presented at the American Society of Nephrology’s (ASN) Kidney Week 2023.
  • Kerendia is the first non-steroidal, selective mineralocorticoid receptor (MR) antagonist to demonstrate dual cardiorenal risk reduction in adult patients with chronic kidney disease (CKD) and type 2 diabetes (T2D).
  • “Kerendia provides healthcare providers with a treatment option to slow chronic kidney disease progression and reduce cardiovascular risk in patients with CKD associated with T2D,” said Robert Perkins, MD, Vice President, Cardiovascular & Renal, Bayer.

Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, UACR, Phase, Albuminuria, Medical imaging, Medical device

Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

Key Points: 
  • Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
  • Zibotentan in combination with dapagliflozin compared to dapagliflozin alone in patients with chronic kidney disease: A randomised active-controlled clinical trial.
  • Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.
  • Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review.

Boehringer Ingelheim achieves major milestone in chronic kidney disease: aldosterone synthase inhibitor on top of empagliflozin delivers promising results in Phase II trial

Retrieved on: 
Friday, November 3, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, Standard of care, University of Washington School of Medicine, Hyperkalemia, Oxford, Pressure, Albuminuria, SGLT2, Kidney, HIV disease progression rates, Society, American Society of Nephrology, Population 1 (album), Chronic kidney disease, Phase, Boehringer Ingelheim, Clinical trial, ASN, Hypertension, Aldosterone, Risk, Kidney disease, University, Serum, ASI, CKD, Safety, End organ damage, Patient, Ingelheim am Rhein, Pharmaceutical industry, UACR, Medicine

Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).

Key Points: 
  • Boehringer Ingelheim today announced promising 14-week Phase II data for BI 690517, a novel selective aldosterone synthase inhibitor (ASi).
  • “With over 1 billion people worldwide affected by these conditions, the potential to help reduce the pressure on healthcare systems and patients is immense.
  • We are proud to be leading the way in this field and are excited to move forward with the upcoming Phase III trial to further investigate the potential of this novel compound on top of standard of care including empagliflozin."
  • Hyperkalemia occurred at a rate typical for a CKD population,1 and most episodes did not require medical treatment or BI 690517 discontinuation.1

Hip-Hop Classic "It Takes Two" Takes on New Meaning in Remix to Elevate Importance of Testing for Kidney Disease

Retrieved on: 
Wednesday, November 1, 2023
Medical Affairs Bureau, Disney Channel Hits: Take 2, Lilly, Eli Lilly and Company, Boehringer Ingelheim, Dean (education), NYSE, EGFR, UC, Human, Kidney, LLY, Diabetes, Inclusion, Glomerular filtration rate, HIV disease progression rates, UACR, FAAFP, Chronic kidney disease, Risk, University of California, Irvine School of Medicine, Kidney disease, Blood, Diversity, CKD, It Takes Two, Patient, Diagnosis, Heart failure, Head, Pharmaceutical industry, Nursing, Medicine, F.A.C.E

More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.

Key Points: 
  • More than three decades later, the sentiment still rings true, especially when it comes to managing kidney health.
  • By turning "It Takes Two" into "It Takes 2 – The Remix," he is helping Boehringer Ingelheim and Lilly reach key audiences to spotlight the significance of complete testing.
  • It Takes 2 encourages healthcare professionals to add UACR testing to screen for CKD, as eGFR testing only tells half the story.
  • By tapping into a powerful combination of nostalgia and memorability, It Takes 2 is helping bring greater recognition to kidney disease."

Everly Health Launches Comprehensive At-Home Collection Kidney Health Test to Address Chronic Kidney Disease

Retrieved on: 
Thursday, October 5, 2023
Biotechnology, Medical Devices, Health, Pharmaceutical, Managed Care, Diagnosis, EGFR, MBA, CKD, MPH, HEDIS, Diabetes, CMS, Healthcare Effectiveness Data and Information Set, Medicare, Kidney, Chronic kidney disease, KED, Centers for Medicare & Medicaid Services, UACR, Glomerular filtration rate, Kidney disease, Pharmaceutical industry, MD

Everly Health , a digital health company at the forefront of remote diagnostics-driven care, today announced the launch of a comprehensive at-home collection kidney health test for health plans and employers to expand access to prevention, diagnosis, and treatment of chronic kidney disease (CKD).

Key Points: 
  • Everly Health , a digital health company at the forefront of remote diagnostics-driven care, today announced the launch of a comprehensive at-home collection kidney health test for health plans and employers to expand access to prevention, diagnosis, and treatment of chronic kidney disease (CKD).
  • “We have an opportunity to significantly change the course of chronic kidney disease in the United States by working to ensure early detection is available to people through the testing they need to protect their kidney health.”
    The Everly Health At-Home Collection Kidney Health Test is the combination of an estimated glomerular filtration rate (eGFR) through blood collection, estimating kidney function, and a urinary albumin-to-creatinine ratio (UACR) to assess kidney function through urine collection.
  • The collection methods used for the Everly Health Kidney Health Test have a correlation of over 98.6% when compared to standard collection methods.
  • The at-home collection kidney health test aims to lower lifetime costs associated with Chronic Kidney Disease and diabetes by increasing accessibility to testing and satisfying the 2024 KED HEDIS measure.

Renalytix Reports Full Year Fiscal 2023 Results

Retrieved on: 
Thursday, September 28, 2023
Insurance, LSE, ICR, Diabetes, Metabolism, Telephone, Appointment, EGFR, Prescription, Risk, SALT, Black, SGLT2, EDT, Dialysis, CareFirst BlueCross BlueShield, Medicare, Community health, PIN, Standard of care, Patient, Wake Forest, UACR, Diabetic nephropathy, FDA, Mid-Atlantic (United States), Kidney disease, BST, Medical device, Health insurance, Pharmaceutical industry, Cryptocurrency, Medical imaging, Obesity

LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.

Key Points: 
  • LONDON and SALT LAKE CITY, Sept. 28, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, reports its financial results for the fiscal year ended June 30, 2023.
  • Deployment and risk stratification by KidneyIntelX was associated with escalation in clinical actions taken to optimize cardio-metabolic-kidney health including medications and referrals.
  • Over 5,000 KidneyIntelX tests performed in fiscal year 2023, up 55% from the prior year
    Investors are advised to read the results for the 12 months ended 30 June 2023, which have been filed with the U.S. Securities and Exchange Commission on Form 10-K concurrently with this results announcement.
  • Upon registering, a dial-in number and unique PIN will be provided in order for interested parties to join the conference call.

Bayer to Investigate Finerenone in Phase III Study in Adults With Chronic Kidney Disease Associated With Type 1 Diabetes

Retrieved on: 
Thursday, June 22, 2023
Research, FDA, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, TESA Collective, Hyperkalemia, Enzyme inhibitor, JDRF, ARB, Chronic kidney disease, Prevalence, Diabetes, Metabolism, T1D, FACP, Clinical trial, EGFR, Type 2 diabetes, Glomerular filtration rate, Kidney, Doctor of Philosophy, Finerenone, Washington University in St. Louis, Albuminuria, Kidney disease, Hypertension, Bayer, Patient, Division, Risk, RAS, Executive Committee, System, Single-use medical devices, UACR, MPH, CKD, Safety, T2D, News, Pharmaceutical industry, Medicine, MD, Endocrinology

Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).

Key Points: 
  • Bayer announced today the initiation of FINE-ONE, a global, multicenter, randomized, placebo-controlled, double-blind, parallel-group Phase III study to evaluate the efficacy and safety of a new investigational use of finerenone versus placebo in adults with chronic kidney disease (CKD) and type 1 diabetes (T1D).
  • Finerenone is marketed as Kerendia® and approved for the treatment of adults with CKD associated with type 2 diabetes (T2D) in more than 70 countries worldwide, including the United States.
  • “Despite progress in risk reduction in type 2 diabetes, chronic kidney disease in type 1 diabetes remains understudied, leaving a huge unmet need for this population.
  • JDRF is committed to collaborating to help this critical trial succeed.”
    “For almost 30 years, there has been no new treatment approved to address the high risk of kidney disease progression in adults with chronic kidney disease and type 1 diabetes.

Renalytix selects EVERSANA® to expand commercialization of KidneyIntelX for Early-Stage Kidney Disease Prognosis Detection in Patients with Type 2 Diabetes

Retrieved on: 
Thursday, May 25, 2023
Insurance, LSE, Glycated hemoglobin, Kidney failure, Additive effect, American Diabetes Association, Chronic kidney disease, Diabetes, Creatinine, The American Journal of Managed Care, Type 2 diabetes, Prognosis, Community health, Journal, American Journal, Patient, Risk, Kidney, UACR, Artificial intelligence, Diabetic nephropathy, Kidney disease, Pharmaceutical industry

Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease.

Key Points: 
  • Using highly reliable, bioprognostic™ methodology, KidneyIntelX yields a simple-to-understand, custom risk score, helping clinicians better predict which adult patients with type 2 diabetes may be at various stages of chronic kidney disease.
  • “We believe that patients deserve the best options every day in their healthcare journey,” said Jim Lang, CEO at EVERSANA.
  • “The majority of people with type 2 diabetes over the age of 65 have chronic kidney disease,” said James McCullough, CEO of Renalytix.
  • Additional real-world KidneyIntelX utility data is expected to be released at the American Diabetes Association annual clinical meeting this June.

Healthy.io Announces Collaboration with Boehringer Ingelheim to Increase Access to Testing for Kidney Disease

Retrieved on: 
Wednesday, May 10, 2023
Kidney disease, ACR, ESRD, Kidney failure, Senior, Chronic kidney disease, Diabetes, Smartphone, Boehringer Ingelheim, Dialysis, Hypertension, Kidney, Patient, Risk, National Kidney Foundation, UACR, Diagnosis, FDA, CKD, Healthy.io, African Americans, Medicine, Pharmaceutical industry, Four-minute warning

Through this collaboration, Boehringer Ingelheim will work with Healthy.io's Minuteful Kidney™ test kit to explore the operational aspects of an at-home UACR (urine albumin-to-creatinine ratio) test kit – the first and only FDA-cleared, smartphone powered at-home ACR test – to at-risk, previously untested patients.

Key Points: 
  • Through this collaboration, Boehringer Ingelheim will work with Healthy.io's Minuteful Kidney™ test kit to explore the operational aspects of an at-home UACR (urine albumin-to-creatinine ratio) test kit – the first and only FDA-cleared, smartphone powered at-home ACR test – to at-risk, previously untested patients.
  • This will help engage these patients in their kidney health by conducting a smartphone-powered test at the time and place of their choosing as a step-in screening for earlier identification of CKD.
  • "Minuteful Kidney is a catalyst to increase ACR testing at scale and support early detection of CKD," said Paula LeClair, U.S. General Manager at Healthy.io.
  • Yet most don't know they have the condition until it progresses to end-stage renal disease (ESRD), eventually requiring dialysis and/or a kidney transplant.